SCOPUS 정보 검색 플랫폼

Volumn 31, Issue 1, 2012, Pages 193-194

Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: Mixed treatment comparison using placebo as common comparator

(4) Migliore, Alberto a Bizzi, Emanuele a Broccoli, Serena b Laganà, Bruno c

a SPietro FBF Hospital (Italy)

b CRO (Italy)

c SAPIENZA UNIVERSITY OF ROME (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO;

COMPARATIVE STUDY; FOLLOW UP; HUMAN; LETTER; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84856744462 PISSN: 07703198 EISSN: 14349949 Source Type: Journal
DOI: 10.1007/s10067-011-1862-7 Document Type: Letter

Times cited : (5)

References (4)

1
- 0034729950
- Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
- PJ Mease BS Goffe J Metz A VanderStoep B Finck DJ Burge 2000 Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 385 390 10972371 10.1016/S0140-6736(00)02530-7 1:CAS:528: DC%2BD3cXls1Cksr8%3D (Pubitemid 30487495)
- (2000) Lancet , vol.356 , Issue.9227 , pp. 385-390
- Mease, P.J.¹ Goffe, B.S.² Metz, J.³ Vanderstoep, A.⁴ Finck, B.⁵ Burge, D.J.⁶

2
- 20244376625
- Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227-36. Erratum in
- 1:CAS:528:DC%2BD2MXhtFymsrfI
- CE Antoni A Kavanaugh B Kirkham Z Tutuncu GR Burmester U Schneider DE Furst J Molitor E Keystone D Gladman B Manger S Wassenberg R Weier DJ Wallace MH Weisman JR Kalden J Smolen 2005 Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227-36. Erratum in Arthritis Rheum 52 9 2951 1:CAS:528:DC%2BD2MXhtFymsrfI
- (2005) Arthritis Rheum , vol.52 , Issue.9 , pp. 2951
- Antoni, C.E.¹ Kavanaugh, A.² Kirkham, B.³ Tutuncu, Z.⁴ Burmester, G.R.⁵ Schneider, U.⁶ Furst, D.E.⁷ Molitor, J.⁸ Keystone, E.⁹ Gladman, D.¹⁰ Manger, B.¹¹ Wassenberg, S.¹² Weier, R.¹³ Wallace, D.J.¹⁴ Weisman, M.H.¹⁵ Kalden, J.R.¹⁶ Smolen, J.¹⁷

3
- 19044382942
- Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial
- DOI 10.1136/ard.2004.032268
- C Antoni GG Krueger K de Vlam C Birbara A Beutler C Guzzo B Zhou LT Dooley A Kavanaugh 2005 IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Ann Rheum Dis 64 8 1150 1157 15677701 10.1136/ard.2004.032268 1:CAS:528:DC%2BD2MXpslGmsrg%3D (Pubitemid 41113349)
- (2005) Annals of the Rheumatic Diseases , vol.64 , Issue.8 , pp. 1150-1157
- Antoni, C.¹ Krueger, G.G.² De Vlam, K.³ Birbara, C.⁴ Beutler, A.⁵ Guzzo, C.⁶ Zhou, B.⁷ Dooley, L.T.⁸ Kavanaugh, A.⁹

4
- 34248653725
- Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy
- MC Genovese PJ Mease GT Thomson AJ Kivitz RJ Perdok MA Weinberg J Medich EH Sasso 2007 Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy J Rheumatol 34 5 1040 1050 17444593 1:CAS:528:DC%2BD2sXmtV2rtLY%3D (Pubitemid 46774851)
- (2007) Journal of Rheumatology , vol.34 , Issue.5 , pp. 1040-1050
- Genovese, M.C.¹ Mease, P.J.² Thomson, G.T.D.³ Kivitz, A.J.⁴ Perdok, R.J.⁵ Weinberg, M.A.⁶ Medich, J.⁷ Sasso, E.H.⁸

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.